| To quickly scroll down to an adult oncology set category select the initial letter below |
|---|
A |
B |
C |
D |
E |
F |
G |
H |
L |
M |
O |
P |
S |
T |
U |
Select the Adult Oncology Order Sets Below
To open the PDF in your browser click on a link below inside any of the categories, to download right-click on the link and pull down to "Save link as..." or in Internet Explorer 11 pull down to "Save target as...".
A
Inpatient
- CALGB 9111 (Cyclophosphamide + DAUNOrubicin + vinCRIStine) - ALL (Age > 60 yo) - 2878
- CALGB 8811 (Larson) (Cyclophosphamide + DAUNOrubicin + vinCRIStine) - ALL (Age <60 yo) - 2878
- HYPER CVAD - Even Cycles (Methotrexate + Cytarabine + Leucovorin) - ALL - 2879
- HYPER CVAD - Odd Cycles (Cyclophosphamide + vinCRIStine + Adriamycin (DOXOrubicin) - ALL -2884
Inpatient
- Cladribine + Low-Dose Sub-Q Cytarabine - AML - 2887
- CLAG (Filgrastim+ Cladribine + Cytarabine) - 3636
- CLAG - M (Filgrastim + Cladribine + Cytarabine + Mitoxantrone) - 3637
- FLAG – Refractory/Relapse (Filgrastim + Fludarabine + Cytarabine) – 3638
- FLAG – IDA – Refractory/Relapse (Filgrastim + Fludarabine + Cytarabine + IDArubicin) – 3639
- CIA (Clofarabine + IDArubicin + Ara-C (Cytarabine) - AML - 2898
- Decitabine(Dacogen) patient >/+ 60 y.o. (AML) - 3460
- HDAC - High-Dose Ara-C (Cytarabine) - AML - 2897
- 7 + 3 (Cytarabine + DAUNOrubicin) - AML - 2899
- 7 + 3 (Cytarabine + IDArubicin) - AML - 2902
- FCE - (Fludarabine + Cytarabine + Etoposide) - AML - 3148
Outpatient
B
Inpatient
- Gemcitabine + CISplatin - Bladder - 3705
- Gemcitabine + CISplatin split dose - Bladder - 3706
- MVAC Dose dense (MTX + Vinblastine + DOXOrubicin + CISplatin) – 3720
- Gemcitabine + CARBOplatin - Bladder - 3703
- PCG (PACLitaxel + CISplatin + Gemcitabine) - Bladder - 3721
- Gemcitabine + CARBOplatin split dose - Bladder - 3704
Outpatient
- MVAC Dose dense (MT + Vinblastine + DOXOrubicin + CISplatin) - 3724
- Gemcitabine + CARBOplatin – Bladder – 3707
- Gemcitabine + CARBOplatin split dose - Bladder - 3708
- Gemcitabine + CISplatin – Day 1 – Bladder – 3709
- Gemcitabine + CISplatin – Day 8 – Bladder – 3711
- Gemcitabine + CISplatin split dose - Bladder - 3710
Inpatient
- AC (Adriamycin + Cytoxan) - Breast - 3143
- AT (Adriamycin + TaxOL) - Breast - 3144
- TC (taxoTERE + Cytoxan) - Breast - 3145
Outpatient
- AC (Adriamycin + Cytoxan) - Breast – 3039
- AC + Ketyruda (Adriamycin + Cytoxan + Pembrolizumab (KEYTRUDA) - Breast – 3039
- AT (Adriamycin + TaxOL) - Breast - 3038
- Herceptin and TaxOL - Breast – 3115
- Herceptin Q1 Weeks - Breast - 3041
- Herceptin Q3 Weeks - Breast - 3041
- Trastuzumab - Pertuzumab (PERJETA) -Breast - 4044
- TC (taxoTERE + Cytoxan) - Breast - 3040
- TCHP (taxoTERE + CARBOplatin + Herceptin + Perjeta – 2367
- Atezolizumab and Abraxane - Breast - 3985
- PACLItaxel (Weekly) + CARBOplatin (Weekly) + pembrolizumab (q 3Weeks) - Breast - 4065
- ADO-trastuzumab (KADCYLA) Q 3 Weeks - Breast - 4127
C
Outpatient
- CapeOX (Capecitabine + Oxaliplatin) - Rectal – 3020
- FOLFIRI (Fluorouracil + Leucovorin+ Irinotecan) - Colorectal - 3185
- FOLFOX 4 (Fluorouracil + Leucovorin + Oxaliplatin) - Colorectal - 3186
- FOLFOX 6 (Fluorouracil + Leucovorin + Oxaliplatin) - Colorectal - 3187
- FOLFOXIRI (Fluorouracil + Leucovorin + Oxaliplatin + Irinotecan) - Colorectal - 3188
- XELIRI (Irinotecan + Capecitabine) - Colon - 4194
Inpatient
E
F
G
Clinical Calculator
Outpatient
- Bevacizumab (Avastin) Single Agent – 3448
- Bevacizumab Single Agent Q 2 Weeks – 3448
- Bevacizumab Single Agent Q 3 Weeks – 3448
- Intrathecal Cytarabine - 3357
- Intrathecal Methotrexate - 3355
- RiTUXimab – 3231
- Pembrolizumab (KEYTRUDA) Single Agent Every 6 Weeks – 3029
- Pembrolizumab (KEYTRUDA) Single Agent Every 3 Weeks – 3029
Inpatient
H
Outpatient
- Erbitux + CARBOplatin + Fluorouracil(24HR BAG CHANGE) - Head and Neck - 3191
- Erbitux + CARBOplatin + Fluorouracil(96HR BAG) - Head and Neck - 3191
- TPF (TaxoTERE + Platinol + Fluorouracil (24hr bag change) - Head and Neck - 4046
- TPF (TaxoTERE + Platinol + Fluorouracil (120 hr bag) - Head and Neck - 4046
- CISplatin Weekly Concurrently with XRT - 4063
Inpatient
L
Outpatient
- NSCLC - PEMEtrexed + CARBOplatin - Lung - 3226
- NSCLC (Lung) - Weekly CARBOplatin + TaxOL Concurrent RT - 3603
- NSCLC - Bevacizumab + CARBOplatin + PACLItaxel - Lung - 3019
- NSCLC - Pembrolizumab + NAB-PAClItaxel + CARBOplatin - 4064
- SCLC - Atezolizumab + CARBO + Etoposide - Lung - 3557
- SCLC - CARBOplatin + Etoposide - Lung - 3521
- SCLC - CISplatin + Etoposide - Lung - 3522
- SCLC or NSCLC - Atezolizumab maintenance phase - 3561
Inpatient
- NSCLC (Lung) - Weekly CARBOplatin + TaxOL Concurrent RT - 3604
- NSCLC (Lung) - CARBOplatin + TaxOL + Bevacizumab - 3156
- NSCLC (Lung) - CARBOplatin + TaxOL - 3215
- NSCLC (Lung) - CISplatin (Days 1 and 8) + Vinorelbine (weekly) - 3155
- NSCLC (Lung) - CISplatin + Gemcitabine - 3153
- NSCLC (Lung) - CARBOplatin + PEMEtrexed - 3152
- NSCLC (Lung) - CISplatin + PEMEtrexed - 3154
- SCLC (Lung) - CARBOplatin + Etoposide - 3506
- SCLC (Lung) - CISplatin + Etoposide - 3507
Outpatient
- ABVD (Adriamycin + Bleomycin + vinBLAStine + Dacarbazine) - Hodgkin's Lymphoma - 3192
- GemOX + RiTUXimab (Gemcitabine + Oxaliplatin + riTUXimab) - 3193
- R - CHOP (riTUXimab + Cyclophosphamide + DOXOrubicin +Oncovin (vinCRIStine) + predniSONE)- Lymphoma - Non-Hodgkin's - 4047
- Bendamustine + riTUXimab or Biosimiliar - Non Hodgkins - 4195
Inpatient
- ABVD (Adriamycin + Bleomycin + vinBLAStine + Dacarbazine) - Hodgkin's Lymphoma - 2990
- R - CHOP (riTUXimab + Cyclophosphamide + DOXOrubicin +Oncovin (vinCRIStine) + predniSONE)- Lymphoma - Non-Hodgkin's - 2996
- R - EPOCH (riTUXimab + Etoposide + predniSONE + DOXOrubicin + Cyclophosphamide) - Lymphoma - Non-Hodgkin's - 2992
- CODOX - M (Cyclophosphamide + Oncovin (vinCRIStine) + DOXOrubicin + Methotrexate + Leucovorin) - Lymphoma - Non-Hodgkin's, Burkitt's - 2991
- ESHAP (Etoposide + Solu-Medrol + Ara-C (Cytarabine) + Platinol) - Lymphoma - 2863
- IVAC (Ifosfamide + Mesna + VePesid (Etoposide) + Ara-C (Cytarabine) - Burkitt's Lymphoma - 2995
- CNS Lymphoma - High-Dose Methotrexate + riTUXimab - 2993
- High Dose METHOTREXATE for CNS Prophylaxis-3999
- CNS Prophylaxis - Intrathecal Methotrexate/Cytarabine - 2994
- GEMOX + Rituxan (Gemcitabine + Oxaliplatin + riTUXimab) - Lymphoma - 2997
- IGEV (Ifosfamide + Gemcitabine + Vinorelbine + Mesna + predniSONE) - 3467
- R - ICE (riTUXimab + Ifosfamide + CARBOplatin + Etoposide) - Lymphoma - 2998
M
Outpatient
- CYBOR-D - Induction (Cyclophosphamide + Bortezomib + Dexamethasone) - Multiple Myeloma - 3196
- Daratumumab (DARZALEX) SPLIT DOSE – 2530
- CYBOR-D - Amyloidosis (Cyclophosphamide + Bortezomib + Dexamethasone) - Multiple Myeloma - 3196
- Daratumumab (DARZALEX) Weeks 1-8 – 3218
- Daratumumab (DARZALEX) Weeks 25 and beyond – 3218
- Daratumumab (DARZALEX) Weeks 9-24 – 3218
- Isatuximab + Pomalidomide + Dexamethasone - Myeloma -3879
Inpatient
O
Outpatient
- Advanced Adjuvant (IV Dose Dense) CARBOplatin + Weekly taxOL (OVARIAN) – 2983
- Dose-Dense (weekly) TaxOL + CARBOplatin - Ovarian - 2983
- DOXOrubicin liposomal + Avastin (bevacizumab) – Ovarian Recurrent Cancer – Platinum Resistant Day 1 and Day 15 – 3415
- Platinum Sensitive Ovarian Cancer - CALYPSO (CARBOplatin + DOXOrubicin liposomal) - 3003
- Platinum Sensitive Ovarian Cancer – (CARBOplatin + Gemcitabine) Day 1 and 8) – 3005
- Platinum Sensitive Ovarian Cancer - GOG 126L (CISplatin + Gemcitabine) - 2982
- Platinum Sensitive or Platinum Resistant Ovarian Cancer - Single Agent - GOG 170D (Avastin) - 3052
- Platinum Sensitive or Platinum Resistant Ovarian Cancer - Single Agent - MITO ARM 1 - Regimen 1 (DOXOrubicin liposomal) - 3053
- Platinum Sensitive or Platinum Resistant Ovarian Cancer - Single Agent -GOG 146Q - Regimen 2 (Topotecan) - 3006
- Dose-Dense (weekly) Single Agent TaxOL - Ovarian – 3117
- GOG 175 - Regimen 1 (CARBOplatin + TaxOL) - Ovarian - 2984
- GOG 182 - Regimen 1 (CARBOplatin + TaxOL) - Ovarian - 2984
- Intraperitoneal Regimen - GOG 252 (Regimen 3) - Day 2 - CISplatin - 3094
- Intraperitoneal Regimen - GOG 252 (Regimen 3) - Day 8 – TaxOL – 3095
- GOG 252 (Regimen 3) - Day 1 - TaxOL IV - Ovarian - 2986
- Ovarian - TaxOL IV - GOG 252 (Regimen 3) - Day 1 – 2986
- Ovarian - CISplatin Intraperitoneal - GOG 252 (Regimen 3) - Day 2 - 3094
- Ovarian - TaXOL Intraperitoneal - GOG 252 (Regimen 3) - Day 8 - 3095
- Nagourney et al 2003 (Gemcitabine + CISplatin) - 3017
- Hamansishi et al JCO 2015 - Nivolumab - Ovarian - 3021
Inpatient
P
S
Outpatient
- Sarcoma Soft Tissue – Olaratumab + DOXOrubicin Day 1 – 3050
- Sarcoma Soft Tissue – Olaratumab + DOXOrubicin Day 8 – 3065
Inpatient
- MAP (CISplatin + DOXOrubicin) - Osteosarcoma - 3620
- MAP (High Dose Methotrexate) - Osteosarcoma – 3615
- Ewing Even Cycles IE (Ifosfamide + Etoposide) - Sarcoma - 3687
- Ewing Odd Cycles VAC (vincristine + DOXOrubicin + Cyclophosphamide + Mesna) - Sarcoma - 3686
- MAID (Mesna + Adriamycin + Ifosfamide + Dacarbazine) - Sarcoma - 3001
- AIM _(DOXOrubicin_Ifosfamide_Mesna) - Sarcoma - 3874